# Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

> **NCT06559007** · PHASE1 · COMPLETED · sponsor: **Atridia Pty Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** HRS-5041 dose level 1
- **DRUG:** HRS-5041 dose level 2

## Key facts

- **NCT ID:** NCT06559007
- **Lead sponsor:** Atridia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-25
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-03-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06559007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06559007, "Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06559007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*